Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Intermediates of Afatinib Afatinib CAS 439081-18-2 Afatinib Dimaleate CAS 850140-73-7 (S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2 (Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6 trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7 Diethylphosphonoacetic Acid CAS 3095-95-2 7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3 7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2 N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1 (S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-Diamine CAS 314771-76-1 (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine CAS 314771-88-5| Item | Specifications |
| Appearance | Yellow to Reddish Yellow Crystal or Powder |
| 1 H NMR Spectrum | Consistent With Structure |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <0.50% |
| Total Impurities | <1.00% |
| Proton NMR Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Afatinib Dimaleate (CAS: 850140-73-7) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 7-Fluoro-6-Nitroquinazolin-4(1H)-one |
| Synonyms | 7-Fluoro-6-Nitroquinazolin-4(3H)-one; 7-Fluoro-4-Hydroxy-6-Nitroquinazoline; 7-Fluoro-6-Nitroquinazolin-4-ol; 7-Fluoro-6-Nitro-4-Hydroxyquinazoline; 7-Fluoro-6-Nitro-1H-Quinazolin-4-one |
| CAS Number | 162012-69-3 |
| CAT Number | RF-PI2025 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C8H4FN3O3 |
| Molecular Weight | 209.13 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
7-Fluoro-6-Nitroquinazolin-4(1H)-one (CAS: 162012-69-3) is an intermediate of Afatinib Dimaleate (CAS: 850140-73-7). Afatinib is an irreversible ErbB family of blockers that suppress information transmission and block the major pathways involved in cancer cell growth and division. Because ErbB family information transduction mechanism can be triggered by multiple homodimers and heterodimers, simultaneous inhibition of multiple ErbB family members (such as EGFR, HER2, ErbB3 and ErbB4) can effectively interrupt the downstream information transduction. Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim. It acts as a angiokinase inhibitor. Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.
